FDA Grants Approval for Eltrombopag Olamine ANDA208815
The FDA's approval of a generic version of Eltrombopag Olamine by Actavis Labs significantly alters the competitive landscape in the hematology market. Pharma strategy teams must evaluate the implications for pricing and market share to safeguard their portfolios against potential revenue impacts.
Company
Actavis Labs
Asset
FDA
Indication
Hematology / Thrombocytopenia
Status
Approved
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
The FDA's approval of a generic version of Eltrombopag Olamine by Actavis Labs significantly alters the competitive landscape in the hematology market. Pharma strategy teams must evaluate the implications for pricing and market share to safeguard their portfolios against potential revenue impacts.
Why it matters
The FDA's approval of a generic version of Eltrombopag Olamine by Actavis Labs significantly alters the competitive landscape in the hematology market. Pharma strategy teams must evaluate the implications for pricing and market share to safeguard their portfolios against potential revenue impacts.
What changed
Regulatory Approval
Analysis
The FDA has granted approval for ANDA208815, a generic version of Eltrombopag Olamine by Actavis Labs.
The FDA's approval of a generic version of Eltrombopag Olamine by Actavis Labs significantly alters the competitive landscape in the hematology market. Pharma strategy teams must evaluate the implications for pricing and market share to safeguard their portfolios against potential revenue impacts.
Monitor market entry timelines and pricing strategies from Actavis and competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.